These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 20408152)
1. Elucidation of the structure and intermolecular interactions of a reversible cyclic-peptide inhibitor of the proteasome by NMR spectroscopy and molecular modeling. Stauch B; Simon B; Basile T; Schneider G; Malek NP; Kalesse M; Carlomagno T Angew Chem Int Ed Engl; 2010 May; 49(23):3934-8. PubMed ID: 20408152 [No Abstract] [Full Text] [Related]
2. Total synthesis, NMR solution structure, and binding model of the potent histone deacetylase inhibitor FR235222. Rodriquez M; Terracciano S; Cini E; Settembrini G; Bruno I; Bifulco G; Taddei M; Gomez-Paloma L Angew Chem Int Ed Engl; 2006 Jan; 45(3):423-7. PubMed ID: 16311994 [No Abstract] [Full Text] [Related]
3. TROSY-based NMR evidence for a novel class of 20S proteasome inhibitors. Sprangers R; Li X; Mao X; Rubinstein JL; Schimmer AD; Kay LE Biochemistry; 2008 Jul; 47(26):6727-34. PubMed ID: 18540636 [TBL] [Abstract][Full Text] [Related]
4. TMC-95-based inhibitor design provides evidence for the catalytic versatility of the proteasome. Groll M; Götz M; Kaiser M; Weyher E; Moroder L Chem Biol; 2006 Jun; 13(6):607-14. PubMed ID: 16793518 [TBL] [Abstract][Full Text] [Related]
5. Molecular modeling studies toward the structural optimization of new cyclopeptide-based HDAC inhibitors modeled on the natural product FR235222. Di Micco S; Terracciano S; Bruno I; Rodriquez M; Riccio R; Taddei M; Bifulco G Bioorg Med Chem; 2008 Sep; 16(18):8635-42. PubMed ID: 18715788 [TBL] [Abstract][Full Text] [Related]
6. Binding mode of TMC-95A analogues to eukaryotic 20S proteasome. Kaiser M; Groll M; Siciliano C; Assfalg-Machleidt I; Weyher E; Kohno J; Milbradt AG; Renner C; Huber R; Moroder L Chembiochem; 2004 Sep; 5(9):1256-66. PubMed ID: 15368577 [TBL] [Abstract][Full Text] [Related]
7. Rapid identification of the pharmacophore in a peptoid inhibitor of the proteasome regulatory particle. Lim HS; Archer CT; Kim YC; Hutchens T; Kodadek T Chem Commun (Camb); 2008 Mar; (9):1064-6. PubMed ID: 18292891 [TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological characterization of argyrin F. Bülow L; Nickeleit I; Girbig AK; Brodmann T; Rentsch A; Eggert U; Sasse F; Steinmetz H; Frank R; Carlomagno T; Malek NP; Kalesse M ChemMedChem; 2010 Jun; 5(6):832-6. PubMed ID: 20358576 [No Abstract] [Full Text] [Related]
9. Proteasome inhibition by peptide-semicarbazones. Leban J; Blisse M; Krauss B; Rath S; Baumgartner R; Seifert MH Bioorg Med Chem; 2008 Apr; 16(8):4579-88. PubMed ID: 18313310 [TBL] [Abstract][Full Text] [Related]
10. NMR solution structure of a potent cyclic nonapeptide inhibitor of ICAM-1-mediated leukocyte adhesion produced by homologous amino acid substitution. Sillerud LO; Burks EJ; Brown WM; Brown DC; Larson RS J Pept Res; 2004 Oct; 64(4):127-40. PubMed ID: 15357668 [TBL] [Abstract][Full Text] [Related]
11. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Groll M; Berkers CR; Ploegh HL; Ovaa H Structure; 2006 Mar; 14(3):451-6. PubMed ID: 16531229 [TBL] [Abstract][Full Text] [Related]
12. Activity enhancement of the synthetic syrbactin proteasome inhibitor hybrid and biological evaluation in tumor cells. Archer CR; Groll M; Stein ML; Schellenberg B; Clerc J; Kaiser M; Kondratyuk TP; Pezzuto JM; Dudler R; Bachmann AS Biochemistry; 2012 Aug; 51(34):6880-8. PubMed ID: 22870914 [TBL] [Abstract][Full Text] [Related]
13. Psoralenquinones as a novel class of proteasome inhibitors: design, synthesis and biological evaluation. Marzaro G; Gandin V; Marzano C; Guiotto A; Chilin A ChemMedChem; 2011 Jun; 6(6):996-1000. PubMed ID: 21472862 [No Abstract] [Full Text] [Related]
14. Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors. Rydzewski RM; Burrill L; Mendonca R; Palmer JT; Rice M; Tahilramani R; Bass KE; Leung L; Gjerstad E; Janc JW; Pan L J Med Chem; 2006 May; 49(10):2953-68. PubMed ID: 16686537 [TBL] [Abstract][Full Text] [Related]
15. Linear TMC-95-based proteasome inhibitors. Basse N; Piguel S; Papapostolou D; Ferrier-Berthelot A; Richy N; Pagano M; Sarthou P; Sobczak-Thépot J; Reboud-Ravaux M; Vidal J J Med Chem; 2007 Jun; 50(12):2842-50. PubMed ID: 17511440 [TBL] [Abstract][Full Text] [Related]
16. The natural product hybrid of Syringolin A and Glidobactin A synergizes proteasome inhibition potency with subsite selectivity. Clerc J; Li N; Krahn D; Groll M; Bachmann AS; Florea BI; Overkleeft HS; Kaiser M Chem Commun (Camb); 2011 Jan; 47(1):385-7. PubMed ID: 20830349 [TBL] [Abstract][Full Text] [Related]
17. Chemical proteomics discloses petrosapongiolide M, an antiinflammatory marine sesterterpene, as a proteasome inhibitor. Margarucci L; Monti MC; Tosco A; Riccio R; Casapullo A Angew Chem Int Ed Engl; 2010 May; 49(23):3960-3. PubMed ID: 20376869 [No Abstract] [Full Text] [Related]